Ongo Weight Loss

Medications offered

As listed on the provider’s own site. Whether a product is FDA-approved or compounded is the single most important distinction here — we explain why.

• SemaglutideType not stated
• Zepbound (tirzepatide)FDA-approved

What they publish

Ongo Weight Loss publishes 1 of 12 standard terms. Fields marked “not publicly disclosed” were not stated on the pages we captured, and we have not filled those gaps with assumptions. Compare disclosure across providers

Membership / programme fee

Pricing was not published on the page we captured

Medication cost

Not publicly disclosed on the pages we captured.

Introductory offer

Not publicly disclosed on the pages we captured.

Insurance

Not publicly disclosed on the pages we captured.

HSA / FSA

Not publicly disclosed on the pages we captured.

Consultation process

Not publicly disclosed on the pages we captured.

Eligibility

Publishes BMI-based criteria on the landing page — for adults with obesity (BMI 30+) or those meeting the lower threshold with a weight-related condition.

Lab work

Not publicly disclosed on the pages we captured.

Pharmacy fulfilment

Not publicly disclosed on the pages we captured.

Shipping

Not publicly disclosed on the pages we captured.

Support services

Not publicly disclosed on the pages we captured.

Cancellation

Not publicly disclosed on the pages we captured.

Refunds

Not publicly disclosed on the pages we captured.

What stands out

• Publishing eligibility criteria up front is better practice than most — it lets people self-assess before investing time in an intake.
• References Zepbound by name and describes it accurately as a dual GLP-1/GIP medication.
• No pricing published on the page we captured.

Questions to ask before you pay

These are things we could not settle from published pages, or that we think are easy to misread. Get answers in writing.

• Establish the monthly cost before starting an intake.
• Confirm whether the medication supplied is the brand-name product.